Developer docs
API playgroundTry for free, no card

Search company profiles

Active Biomarkers

Full company profile

uuid003grqg

Namestring
Active Biomarkers
Legal namestring
KCAS Bio
Company typeenum
Private
Founded yearint
1980
Descriptiontext

Active Biomarkers is a private bioanalytical services provider headquartered in Lyon, France, founded in 2011, that delivers soluble and cellular biomarker analysis in support of clinical trials. Its service portfolio spans small molecule bioanalysis, large molecule analysis by ligand binding assay (LBA), hybrid LC-MS/MS, immunogenicity testing, pharmacokinetics (PK), pharmacodynamics (PD), biomarker testing, flow cytometry, and molecular biology. The company operates GLP/GCP compliant laboratory services and supports work across twelve therapeutic areas including oncology, cardiovascular, immunology, rare diseases, and neurology. According to the aggregated data set, the affiliated laboratory operations have developed over 6,200 proprietary and non-proprietary assays, supported 315+ approved drugs, and completed more than 20-25 FDA audits with no major findings, reflecting a 45-year operational track record in the bioanalytical CRO space.

The underlying technology stack is built around a multi-platform analytical infrastructure including ELISA, ELISpot, Meso Scale Discovery, Luminex, NULISA-Argo HT, LC-MS/MS, qPCR/ddPCR, LC-UV-Vis/fluorescence, Lumipulse G, and globally harmonized Cytek spectral flow cytometry across US, EU, and Australian sites. This instrumentation, combined with 65+ PhD-level scientists, positions the company to handle complex modalities including drug conjugates, large molecule biologics, and cell therapy immune monitoring. The Lyon facility operates as part of a globally distributed laboratory network spanning Kansas City, Philadelphia, Lyon, and Melbourne.

The business model is a professional services / fee-for-service CRO model, with project-based contracts for assay development, validation, and sample analysis. Pricing is quote-based and tailored to individual client requirements with no public pricing tiers. Go-to-market is enterprise field sales targeting pharmaceutical and biotech sponsors, supported by content marketing, scientific publications, podcasts, webinars, and an active LinkedIn and YouTube presence. The firm reports a horizontal segmentation approach, serving drug development programs across all therapeutic areas rather than specializing in a single modality or indication.

Short descriptiontext

Active Biomarkers is a Lyon, France-based bioanalytical CRO providing soluble and cellular biomarker analysis for clinical trials, supporting pharmaceutical and biotech sponsors with GLP/GCP compliant assay development and sample analysis services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomarker analysis services, clinical trial bioanalysis, pharmacokinetics pharmacodynamics, immunogenicity testing, cell-based assays
Industry3 codes
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Medical and Diagnostic Laboratories62151
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Bioanalytical CRO Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Bioanalytical CRO Services
TypeProfessional Services
Description

Contract research organization providing fee-for-service bioanalytical development, testing, and support services for pharmaceutical and biotech drug development programs. Revenue generated through project-based contracts for assay development, validation, and sample analysis services.

kcasbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Active Biomarkers is a bioanalytical service provider based in Lyon, France, founded in 2011, delivering soluble and cellular biomarker analysis in the context of clinical trials. The company operates within a broader bioanalytical CRO platform that supports pharmaceutical and biotech clients with bioanalytical method development, validation, and sample analysis for small and large molecule drug development programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 315+ approved drugs supported through bioanalytical development
+3 more records
Product overview1 text field

KCAS Bio is a bioanalytical contract research organization (CRO) offering a comprehensive portfolio of laboratory testing services organized around three core pillars: Services (bioanalytical testing capabilities), Technology platforms (analytical instrumentation and methodologies), and Therapeutic Area expertise. The Services division includes small and large molecule bioanalysis, immunogenicity testing, pharmacokinetics/pharmacodynamics, biomarker testing, flow cytometry, molecular biology, dose formulation, and central lab services. The Technology pillar provides access to multiple analytical platforms including ligand binding assays (ELISA, ELISpot), Meso Scale Discovery, Luminex, NULISA-Argo HT, LC-MS/MS, qPCR/ddPCR, and LC-UV-Vis/Fluorescence. The company supports drug development across 12 therapeutic areas including oncology, cardiovascular, immunology, and rare diseases. KCAS Bio operates GLP/GCP compliant laboratories across four global locations (Kansas City, Philadelphia, Lyon, and Melbourne) with over 45 years of experience supporting more than 315 approved drugs.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthers
Description

Strategic alliance in Australia through Melbourne laboratory location, providing global sponsors with comprehensive services including bioanalytical, biomarker, immunogenicity, cellular and molecular assay capabilities with clinical kitting and sample management.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Clinical and bioanalytical CRO offering integrated drug development services including biomarker and bioanalytical testing. A broader incumbent competing for outsourced pharma/biotech programs.

TypeBroad incumbent
Description

Global testing services conglomerate with bioanalytical, biomarker, and central lab capabilities across its pharma services division. Overlaps with Active Biomarkers' biomarker and immunogenicity offerings as part of a much larger services portfolio.

TypeDirect peer
Description

Bioanalytical and PK/PD-focused CRO providing small/large molecule bioanalysis, biomarker assays, and clinical pharmacology services for pharma sponsors. Direct competitor in PK and biomarker services.

TypeDirect peer
Description

Affiliated network operating bioanalytical and biomarker CRO services across four global labs (Kansas City, Philadelphia, Lyon, Melbourne). Active Biomarkers serves as the Lyon, France hub of this same network, sharing platform strategy, scientific staff, and GLP/GCP-compliant workflows.

TypeBroad incumbent
Description

Large-scale CRO with deep bioanalytical, safety assessment, and biomarker service lines under the Research Models & Drug Discovery segments. Broader incumbent competitor across the sponsor portfolio that Active Biomarkers targets.

TypeDirect peer
Description

Specialty bioanalytical CRO focused on large molecule PK, immunogenicity, and biomarker assays using LBA, ELISA, MSD, and flow cytometry. Closely comparable to Active Biomarkers in offering menu and pharma/biotech sponsor base.

TypeDirect peer
Description

Bioanalytical, PK, and biomarker CRO serving pharma and biotech with LC-MS/MS, LBA, and immunoassay capabilities. Comparable small-to-mid CRO competitor in bioanalytical development.

TypeDirect peer
Description

Mid-size CRO with bioanalytical and biomarker laboratory services supporting early- and late-phase trials. Comparable in scale and offering mix to the Active Biomarkers niche.

9Labcorp / Covance
TypeBroad incumbent
Description

Global central lab and clinical development services provider with extensive bioanalytical and biomarker offerings. A major incumbent that sponsors benchmark niche CROs against, particularly on bioanalytical capacity and global reach.

TypeBroad incumbent
Description

Combines central lab, bioanalytical, and biomarker testing within IQVIA's clinical development platform. A broad incumbent peer with global reach that competes for multi-year sponsor outsourcing agreements.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Active Biomarkers

Bioanalytical CRO Servicesactive-biomarkers.com

Active Biomarkers is a Lyon, France-based bioanalytical CRO providing soluble and cellular biomarker analysis for clinical trials, supporting pharmaceutical and biotech sponsors with GLP/GCP compliant assay development and sample analysis services.

What Active Biomarkers does

Active Biomarkers is a private bioanalytical services provider headquartered in Lyon, France, founded in 2011, that delivers soluble and cellular biomarker analysis in support of clinical trials. Its service portfolio spans small molecule bioanalysis, large molecule analysis by ligand binding assay (LBA), hybrid LC-MS/MS, immunogenicity testing, pharmacokinetics (PK), pharmacodynamics (PD), biomarker testing, flow cytometry, and molecular biology. The company operates GLP/GCP compliant laboratory services and supports work across twelve therapeutic areas including oncology, cardiovascular, immunology, rare diseases, and neurology. According to the aggregated data set, the affiliated laboratory operations have developed over 6,200 proprietary and non-proprietary assays, supported 315+ approved drugs, and completed more than 20-25 FDA audits with no major findings, reflecting a 45-year operational track record in the bioanalytical CRO space.

The underlying technology stack is built around a multi-platform analytical infrastructure including ELISA, ELISpot, Meso Scale Discovery, Luminex, NULISA-Argo HT, LC-MS/MS, qPCR/ddPCR, LC-UV-Vis/fluorescence, Lumipulse G, and globally harmonized Cytek spectral flow cytometry across US, EU, and Australian sites. This instrumentation, combined with 65+ PhD-level scientists, positions the company to handle complex modalities including drug conjugates, large molecule biologics, and cell therapy immune monitoring. The Lyon facility operates as part of a globally distributed laboratory network spanning Kansas City, Philadelphia, Lyon, and Melbourne.

The business model is a professional services / fee-for-service CRO model, with project-based contracts for assay development, validation, and sample analysis. Pricing is quote-based and tailored to individual client requirements with no public pricing tiers. Go-to-market is enterprise field sales targeting pharmaceutical and biotech sponsors, supported by content marketing, scientific publications, podcasts, webinars, and an active LinkedIn and YouTube presence. The firm reports a horizontal segmentation approach, serving drug development programs across all therapeutic areas rather than specializing in a single modality or indication.

Active Biomarkers firmographics

Firmographics
Name
Active Biomarkers
Legal name
KCAS Bio
Website
https://active-biomarkers.com
Company type
Private
Founded year
1980
Operating status
Operating
Headcount range
11–50 employees
Short description
Active Biomarkers is a Lyon, France-based bioanalytical CRO providing soluble and cellular biomarker analysis for clinical trials, supporting pharmaceutical and biotech sponsors with GLP/GCP compliant assay development and sample analysis services.
Ownership category
akta.pro rank

Active Biomarkers industry classification

Industry
Product category
Bioanalytical CRO Services
NAICS
Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Biomarker analysis services
  • Clinical trial bioanalysis
  • Pharmacokinetics pharmacodynamics
  • Immunogenicity testing
  • Cell-based assays

Where Active Biomarkers is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices4 records

Markets served

Active Biomarkers business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Bioanalytical CRO Services: Contract research organization providing fee-for-service bioanalytical development, testing, and support services for pharmaceutical and biotech drug development programs. Revenue generated through project-based contracts for assay development, validation, and sample analysis services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Active Biomarkers product offering

Product offering

Core offering

Active Biomarkers is a bioanalytical service provider based in Lyon, France, founded in 2011, delivering soluble and cellular biomarker analysis in the context of clinical trials. The company operates within a broader bioanalytical CRO platform that supports pharmaceutical and biotech clients with bioanalytical method development, validation, and sample analysis for small and large molecule drug development programs.

Product overview

KCAS Bio is a bioanalytical contract research organization (CRO) offering a comprehensive portfolio of laboratory testing services organized around three core pillars: Services (bioanalytical testing capabilities), Technology platforms (analytical instrumentation and methodologies), and Therapeutic Area expertise. The Services division includes small and large molecule bioanalysis, immunogenicity testing, pharmacokinetics/pharmacodynamics, biomarker testing, flow cytometry, molecular biology, dose formulation, and central lab services. The Technology pillar provides access to multiple analytical platforms including ligand binding assays (ELISA, ELISpot), Meso Scale Discovery, Luminex, NULISA-Argo HT, LC-MS/MS, qPCR/ddPCR, and LC-UV-Vis/Fluorescence. The company supports drug development across 12 therapeutic areas including oncology, cardiovascular, immunology, and rare diseases. KCAS Bio operates GLP/GCP compliant laboratories across four global locations (Kansas City, Philadelphia, Lyon, and Melbourne) with over 45 years of experience supporting more than 315 approved drugs.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • 315+ approved drugs supported through bioanalytical development
  • +3 more outcomes

Companies that use Active Biomarkers

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Active Biomarkers technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Active Biomarkers partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Strategic Alliance Partner (Australia)coreOthersStrategic alliance in Australia through Melbourne laboratory location, providing global sponsors with comprehensive services including bioanalytical, biomarker, immunogenicity, cellular and molecular assay capabilities with clinical kitting and sample management.

Scale indicators5 records

Recent moves5 records

Expansion highlights6 records

Active Biomarkers competitors and assessment

Company assessment

Broad incumbents

  • Syneos Health: Clinical and bioanalytical CRO offering integrated drug development services including biomarker and bioanalytical testing. A broader incumbent competing for outsourced pharma/biotech programs.
  • Eurofins Scientific: Global testing services conglomerate with bioanalytical, biomarker, and central lab capabilities across its pharma services division. Overlaps with Active Biomarkers' biomarker and immunogenicity offerings as part of a much larger services portfolio.
  • Charles River Laboratories: Large-scale CRO with deep bioanalytical, safety assessment, and biomarker service lines under the Research Models & Drug Discovery segments. Broader incumbent competitor across the sponsor portfolio that Active Biomarkers targets.
  • Labcorp / Covance: Global central lab and clinical development services provider with extensive bioanalytical and biomarker offerings. A major incumbent that sponsors benchmark niche CROs against, particularly on bioanalytical capacity and global reach.
  • IQVIA Laboratories: Combines central lab, bioanalytical, and biomarker testing within IQVIA's clinical development platform. A broad incumbent peer with global reach that competes for multi-year sponsor outsourcing agreements.

Direct peers

  • Celerion: Bioanalytical and PK/PD-focused CRO providing small/large molecule bioanalysis, biomarker assays, and clinical pharmacology services for pharma sponsors. Direct competitor in PK and biomarker services.
  • KCAS Bio: Affiliated network operating bioanalytical and biomarker CRO services across four global labs (Kansas City, Philadelphia, Lyon, Melbourne). Active Biomarkers serves as the Lyon, France hub of this same network, sharing platform strategy, scientific staff, and GLP/GCP-compliant workflows.
  • BioAgilytix: Specialty bioanalytical CRO focused on large molecule PK, immunogenicity, and biomarker assays using LBA, ELISA, MSD, and flow cytometry. Closely comparable to Active Biomarkers in offering menu and pharma/biotech sponsor base.
  • Frontage Laboratories: Bioanalytical, PK, and biomarker CRO serving pharma and biotech with LC-MS/MS, LBA, and immunoassay capabilities. Comparable small-to-mid CRO competitor in bioanalytical development.
  • Worldwide Clinical Trials: Mid-size CRO with bioanalytical and biomarker laboratory services supporting early- and late-phase trials. Comparable in scale and offering mix to the Active Biomarkers niche.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Active Biomarkers social profiles

Digital presence

Active Biomarkers compliance and trust

Trust signal

Compliance2 records

Active Biomarkers financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Active Biomarkers leadership team

Management profile

Number of profiles

Active Biomarkers funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Active Biomarkers M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Active Biomarkers

What does Active Biomarkers do?

Active Biomarkers is a bioanalytical service provider based in Lyon, France, founded in 2011, delivering soluble and cellular biomarker analysis in the context of clinical trials. The company operates within a broader bioanalytical CRO platform that supports pharmaceutical and biotech clients with bioanalytical method development, validation, and sample analysis for small and large molecule drug development programs.

Is Active Biomarkers a public or private company?

Active Biomarkers is a private company. It is classified as unknown and is currently operating.

When was Active Biomarkers founded?

Active Biomarkers was founded in 1980. It employs 11 to 50 people.

Where is Active Biomarkers based?

Active Biomarkers is headquartered in Lyon, France, in the Europe region.

How does Active Biomarkers make money?

One revenue line is on record: bioanalytical CRO Services.

Who are Active Biomarkers's main competitors?

Broad incumbents on record are Syneos Health, Eurofins Scientific, Charles River Laboratories, Labcorp / Covance and IQVIA Laboratories. Direct peers are Celerion, KCAS Bio, BioAgilytix, Frontage Laboratories and Worldwide Clinical Trials.

Does Active Biomarkers have an API?

No public API is recorded for Active Biomarkers.

What industry is Active Biomarkers in?

Active Biomarkers's product category is Bioanalytical CRO Services. Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 62151 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogKCAS Expands Its Transatlantic Presence with the Acquisition of France-based Active BiomarkersKCAS Bioanalytical and Biomarker Services acquired Active Biomarkers, a Lyon-based assay development and bioanalytical laboratory, with financial terms undisclosed. The acquisition adds European capacity and expertise in oncology, infectious disease, inflammation, and neurodegenerative disorders. It is KCAS's second acquisition in 2022, following FlowMetric.FinanzNachrichten.deKCAS Bioanalytical and Biomarker Services: KCAS erweitert transatlantische Präsenz durch die Übernahme des französischen Labors Active BiomarkersKCAS Bioanalytical and Biomarker Services has completed the acquisition of Active Biomarkers, a bioanalytical laboratory based in Lyon, France. This transaction expands KCAS's European presence and adds specialized know-how in bioassays for high-molecular compounds and cell/gene therapies. It marks KCAS's second acquisition in 2022, following the purchase of FlowMetric earlier in the year.PharmiWeb.comKCAS Expands Its Transatlantic Presence with the Acquisition of France-based Active BiomarkersKCAS Bioanalytical and Biomarker Services has completed the acquisition of Lyon-based Active Biomarkers, a specialty bioanalytical laboratory specializing in large molecule and cell/gene therapy assays. This transaction expands KCAS's European footprint and adds world-class bioanalytical expertise to its existing global network of facilities. Financial terms were not disclosed for this second acquisition by KCAS in 2022.